Silverback Asset Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Silverback Asset Management’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-986	Closed	-$1.84K	–	110
2022 Q4	$1.84K	Hold	986	–	–	﹤0.01%	127
2022 Q3	$2.53K	Hold	986	–	–	﹤0.01%	127
2022 Q2	$2K	Hold	986	–	–	﹤0.01%	95
2022 Q1	$3K	Hold	986	–	–	﹤0.01%	88
2021 Q4	$4K	Hold	986	–	–	﹤0.01%	78
2021 Q3	$5K	Buy	+986	New	+$5.43K	﹤0.01%	79

Other funds holding PRTK

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Silverback Asset Management's PRTK Position: Q1 2023 in Review

Silverback Asset Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2023, closing a stake of 986 shares — an estimated $1.84K sold.

Silverback Asset Management first reported a position in PRTK in Q3 2021 and held it in 6 quarters. The position peaked at $5K in Q3 2021. 63 funds tracked by Wall St. Rank hold PRTK as of Q1 2023.

Silverback Asset Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
Silverback Asset Management sold 986 Paratek Pharmaceuticals, Inc. shares in Q1 2023, an estimated $1.84K.
Silverback Asset Management first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2021 and held it in 6 quarters.
Silverback Asset Management's Paratek Pharmaceuticals, Inc. position peaked at $5K in Q3 2021.
63 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2023.

Based on Silverback Asset Management's 13F filing for Q1 2023, filed 15 May 2023.